Cytiva Acquires Vanrx Pharmasystems

Cytiva announced in a Feb. 1, 2021 press release that it had acquired Vanrx Pharmasystems, a Canadian company that makes robotic aseptic filling machines. It is Cytiva’s first acquisition since becoming a Danaher operating company in April 2020, and it will complement Cytiva’s biopharmaceutical manufacturing solutions.

Cytiva noted in the release that, with the trend to smaller batches, a complete bioprocessing workflow should include aseptic filling solutions. Olivier Loeillot, vice-president and head of BioProcess, Cytiva, said in the release that the Vanrx technology would make Cytiva an “idea to injection” company and enhance its Cytiva FlexFactory platforms and KUBio modular facilities for bioprocessing.

Vanrx’s flagship products automate aseptic filling using robotics within closed, gloveless isolators. The SA25 Aseptic Filling Workcell and Microcell Vial Filler are standardized, flexible systems that provide a fast path to filling capacity as the final step in manufacturing clinical and commercial biopharmaceuticals.

Chris Procyshyn, Vanrx CEO, who founded the company in 2007 with co-founder Ross Gold, said in the release, “We created Vanrx to enable every company to manufacture safe and cost-effective injectable therapies. Our own experience told us that new technologies are needed to support next-generation therapies and personalized medicine. Cytiva is a perfect home for what we have built. Thanks to their reach, we will be able to help our current and future customers change the lives of even more patients around the world.”

Vanrx currently has over 120 associates, and all have been offered employment with Cytiva.

Source: Cytiva